Showing results (21-30 of 28) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Frontiers in Oncology|January 22, 2026
Correction: Benchmarking GPT-5 in radiation oncology: measurable gains, but persistent need for expert oversightUgur Dinç, Jibak Sarkar, Philipp Schubert, et al.Frontiers in Oncology|December 29, 2025
Benchmarking GPT-5 in radiation oncology: measurable gains, but persistent need for expert oversightUdo S Dinc, Jibak Sarkar, Philipp Schubert, et al.Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|November 6, 2024
The Segment Anything foundation model achieves favorable brain tumor auto-segmentation accuracy in MRI to support radiotherapy treatment planningFlorian Putz, Sogand Beirami, Manuel Alexander Schmidt, et al.Physics and Imaging in Radiation Oncology|September 22, 2025
Advancing offline magnetic resonance-guided prostate radiotherapy through dedicated imaging and deep learning-based automatic contouring of targets and neurovascular structuresPhilipp Schubert, Matthias May, Daniel Höfler, et al.Journal of Clinical Medicine|October 23, 2021
Reduction of Elective Radiotherapy Treatment Volume in Definitive Treatment of Locally Advanced Head and Neck Cancer-Comparison of a Prospective Trial with a Revised Simulated Contouring ApproachThomas Weissmann, Stefan Speer, Florian Putz, et al.Frontiers in Immunology|October 27, 2025
From essential basic understanding to clinical application - biological, physical and pathophysiological principles of (low-dose) radiotherapy in benign diseasesLisa Deloch, David Rene Steike, Felix Pascher, et al.Journal of Neuro-Oncology|May 1, 2025
Reirradiation for recurrent glioblastoma: the significance of the residual tumor volumeSina Mansoorian, Manuel Schmidt, Thomas Weissmann, et al.Frontiers in Oncology|September 3, 2024
De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a prospective multicenter phase II trial (DIREKHT Trial)Marlen Haderlein, Jens von der Grün, Panagiotis Balermpas, et al.Pageof 3